Flexibility at Genentech: Developing Versatile Domain Experts and Deploying Flexible Resources at One U.S. Medical Affairs Unit Custom Case Solution & Analysis

Evidence Brief: Case Extraction

1. Financial Metrics

Total USMA Headcount: Approximately 500 to 600 employees across various therapeutic areas.
Budget Allocation: Historically fixed to specific drug products or therapeutic areas, leading to resource trapped in declining or stable assets.
Resource Utilization: Significant variance in workload between launch phases (high demand) and post-launch maintenance (lower demand).
Cost of Inflexibility: Estimated 15 to 20 percent of total USMA capacity was misaligned with current strategic priorities prior to the Flex initiative.

2. Operational Facts

Structure: Transitioned from 100 percent fixed therapeutic area alignment to a model where a portion of the staff exists in a flexible pool.
Flex Pool Size: Initially targeted at 15 to 20 percent of the total USMA workforce.
Rotation Duration: Assignments for Versatile Domain Experts typically last between 6 and 18 months depending on clinical trial milestones or launch dates.
Geography: Primary focus on the United States Medical Affairs unit within the Genentech South San Francisco campus.
Skill Requirements: Shift from deep, narrow specialization to a requirement for rapid knowledge acquisition in new therapeutic domains.

3. Stakeholder Positions

Sandra Horning (Chief Medical Officer): Advocates for agility to meet the rapid pace of clinical data generation.
Therapeutic Area Leads: Express concern regarding the loss of deep institutional memory and the potential for reduced quality in medical communications.
Flex Team Members: Report high levels of engagement due to variety but express anxiety regarding career progression and performance evaluation outside traditional silos.
Medical Science Liaisons: Face the highest burden of maintaining external relationships with Key Opinion Leaders while potentially shifting focus between disease states.

4. Information Gaps

Specific training costs for transitioning a specialist from one therapeutic area (e.g., Oncology) to another (e.g., Immunology).
Quantitative impact on Key Opinion Leader satisfaction scores following the transition to flexible resource deployment.
Long-term retention rates of Versatile Domain Experts compared to traditional specialists.
Detailed breakdown of the administrative overhead required to manage the project matching marketplace.

Strategic Analysis

1. Core Strategic Question

How can Genentech decouple medical expertise from rigid organizational silos to optimize resource allocation without compromising the technical depth required for regulatory and clinical success?

2. Structural Analysis

The Value Chain analysis reveals that Medical Affairs serves as the critical link between late-stage R and D and commercial execution. In the traditional model, human capital is a fixed cost tied to specific assets. When an asset fails or matures, that capital becomes stranded. The Jobs-to-be-Done for USMA is the rapid synthesis and dissemination of complex data. This job requires high-intensity effort during data release windows. A fixed structure fails this requirement because it cannot move capacity to where the data is most active.

3. Strategic Options

Option A: The Full Liquid Model. Eliminate all therapeutic area silos and move 100 percent of USMA to a project-based deployment system. This maximizes utilization but risks destroying the deep expertise and external relationships that define the Genentech brand.

Option B: The Hybrid Core-and-Flex Model (Current Path). Maintain a permanent core of 80 percent specialists in each therapeutic area while expanding the Flex pool to 20 percent. This provides a buffer for peak demand periods while preserving institutional memory.

Option C: Strategic Outsourcing of Peak Demand. Keep USMA headcount lean and fixed, using high-end medical contract organizations to handle launch surges. This protects the internal culture but increases costs and risks data security and quality control.

4. Preliminary Recommendation

Genentech should proceed with Option B but must formalize the Versatile Domain Expert career path. The current model risks treating flexible staff as secondary to specialists. By creating a distinct, high-status track for these experts, Genentech can ensure that flexibility is viewed as a premium skill set rather than a temporary assignment. This path balances the need for specialized knowledge with the operational necessity of resource mobility.

Implementation Roadmap

1. Critical Path

Month 1-2: Skill Inventory and Gap Analysis. Map the existing competencies of all USMA staff into a centralized database to identify transferable skills.
Month 3-4: Performance Management Redesign. Establish new evaluation criteria that reward agility, rapid learning, and cross-functional contribution to replace silo-based metrics.
Month 5-6: Marketplace Launch. Deploy an internal platform where therapeutic area leads post projects and Flex members bid based on skills and interest.
Month 7+: Continuous Feedback Loop. Quarterly reviews of project outcomes and expert satisfaction to adjust pool size.

2. Key Constraints

Therapeutic Depth: The time required to reach credible expertise in complex fields like Oncology cannot be bypassed. This limits the speed of redeployment.
Cultural Resistance: Senior specialists may view the Flex model as a threat to their status or a dilution of medical rigor.
Regulatory Compliance: Strict walls between medical and commercial functions must be maintained regardless of how resources move.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of expertise dilution, Genentech must implement a mandatory shadowing period of 30 days for any expert moving to a new therapeutic area. This ensures safety and quality standards are met before the expert takes on external-facing responsibilities. Additionally, a contingency of 5 percent of the total budget should be reserved to hire external contractors if the internal Flex pool cannot meet a sudden, simultaneous surge across multiple therapeutic areas.

Executive Review and BLUF

1. BLUF

The transition to a flexible resource model at Genentech is a necessary evolution to manage the volatility of clinical data cycles. The current siloed structure results in 20 percent resource misalignment, which is unsustainable in a tightening regulatory and reimbursement environment. The Hybrid Core-and-Flex model is the only viable path to maintain medical depth while achieving operational agility. Success depends entirely on the formalization of the Versatile Domain Expert role. Without a clear career path and specialized training, the Flex pool will become a repository for underperformers, undermining the entire strategic intent. Approved for leadership review with the condition that the performance management framework is finalized prior to further expansion of the Flex pool.

2. Dangerous Assumption

The most consequential unchallenged premise is that medical expertise is fungible across vastly different disease states. The analysis assumes a physician can transition from Immunology to Oncology and maintain the same level of credibility with world-class investigators. If this assumption is false, Genentech risks losing its position as a preferred partner for top-tier clinical researchers.

3. Unaddressed Risks

Talent Attrition: Competitors still utilize traditional specialist models. High-performing experts who value deep specialization may be recruited away by firms offering permanent, siloed roles. (Probability: High; Consequence: High).
Knowledge Fragmentation: As experts rotate, the long-term history of a drug development program may be lost, leading to repetitive mistakes in clinical trial design or regulatory filings. (Probability: Moderate; Consequence: Severe).

4. Unconsidered Alternative

The team failed to consider a Center of Excellence model where specific functions (e.g., medical writing, data analysis, publication planning) are centralized and serve all therapeutic areas as a shared service. This would provide the desired flexibility and efficiency without requiring experts to change their disease-state focus, potentially preserving more technical depth than the current Flex model.